Literature DB >> 24661331

Advances in renal neoplasia: recommendations from the 2012 International Society of Urological Pathology Consensus Conference.

Brett Delahunt1, John R Srigley2, Rodolfo Montironi3, Lars Egevad4.   

Abstract

The International Society of Urological Pathology (ISUP) 2012 Consensus Conference made recommendations regarding the classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. There was consensus that 5 entities should be recognized as novel tumors: tubulocystic renal cell carcinoma (RCC), acquired cystic disease-associated RCC, clear cell papillary RCC, microphthalmia transcription factor-family translocation RCC [in particular t(6; 11) RCC], and hereditary leiomyomatosis RCC syndrome-associated RCC. In addition, 3 rare epithelial carcinomas were considered emerging or provisional entities: thyroid-like follicular RCC, succinate dehydrogenase B deficiency-associated RCC, and anaplastic lymphoma kinase translocation RCC. There were also a number of suggested modifications to existing World Health Organization 2004 categories, with the new classification to be known as the ISUP Vancouver Classification. Tumor morphotype, sarcomatoid/rhabdoid differentiation, and tumor necrosis were identified as significant prognostic parameters for RCC. The ISUP Grading System was accepted with grades 1-3 of clear cell and papillary RCC being based on nucleolar prominence, whereas extreme nuclear pleomorphism or sarcomatoid and/or rhabdoid differentiation defined grade 4 tumors. It was agreed that chromophobe RCC should not be graded. Consensus guidelines were formulated for specimen handling, and it was agreed that renal sinus invasion is present when tumor is in direct contact with fat or loose connective tissue of the sinus or if there is involvement of endothelial-lined spaces within the renal sinus, regardless of the size. The role of biomarkers in the diagnosis and assessment of prognosis of renal tumors was considered, and panels of immunohistochemical markers were identified for use in specific differential diagnostic scenarios.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24661331     DOI: 10.1016/j.urology.2014.02.004

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

Review 1.  Acquired cystic kidney disease: an under-recognized condition in children with end-stage renal disease.

Authors:  Eugene Y H Chan; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2017-04-25       Impact factor: 3.714

2.  Distribution of Vascular Patterns in Different Subtypes of Renal Cell Carcinoma. A Morphometric Study in Two Distinct Types of Blood Vessels.

Authors:  Amparo Ruiz-Saurí; V García-Bustos; E Granero; S Cuesta; M A Sales; V Marcos; A Llombart-Bosch
Journal:  Pathol Oncol Res       Date:  2017-07-01       Impact factor: 3.201

3.  S100A11 is a potential prognostic marker for clear cell renal cell carcinoma.

Authors:  Manal Gabril; Hala Girgis; Andreas Scorilas; Fabio Rotondo; Samantha Wala; Georg A Bjarnason; Qiang Ding; Andrew Evans; Eriny Tawedrous; Maria Pasic; Antonio Finelli; Sahar Al-Haddad; George M Yousef
Journal:  Clin Exp Metastasis       Date:  2016-01       Impact factor: 5.150

Review 4.  99mTc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide.

Authors:  Scott P Campbell; Antonios Tzortzakakis; Mehrbod S Javadi; Mattias Karlsson; Lilja B Solnes; Rimma Axelsson; Mohamad E Allaf; Michael A Gorin; Steven P Rowe
Journal:  Br J Radiol       Date:  2018-02-27       Impact factor: 3.039

5.  [Cross-sectional imaging evaluation of renal masses].

Authors:  P Nuhn; A Sterzik; C G Stief; M Staehler; M D'Anastasi
Journal:  Urologe A       Date:  2015-07       Impact factor: 0.639

Review 6.  Tubulocystic renal cell carcinoma: a new radiological entity.

Authors:  F Cornelis; O Hélénon; J M Correas; L Lemaitre; M André; J Y Meuwly; C Sengel; L Derchi; M Yacoub; V Verkarre; N Grenier
Journal:  Eur Radiol       Date:  2015-07-24       Impact factor: 5.315

7.  Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Authors:  Zhiyuan Lin; Li Liu; Yu Xia; Xiang Chen; Ying Xiong; Yang Qu; Jiajun Wang; Qi Bai; Jianming Guo; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

8.  An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways.

Authors:  Samantha Jane Wala; Jason Raj Karamchandani; Rola Saleeb; Andrew Evans; Qiang Ding; Rania Ibrahim; Michael Jewett; Maria Pasic; Antonio Finelli; Kenneth Pace; Evi Lianidou; George Makram Yousef
Journal:  Mol Oncol       Date:  2015-05-14       Impact factor: 6.603

Review 9.  Renal cell carcinoma: histological classification and correlation with imaging findings.

Authors:  Valdair F Muglia; Adilson Prando
Journal:  Radiol Bras       Date:  2015 May-Jun

10.  The Difference in Prognosis between Renal Sinus Fat and Perinephric Fat Invasion for pT3a Renal Cell Carcinoma: A Meta-Analysis.

Authors:  Zhiling Zhang; Chunping Yu; Liliya Velet; Yonghong Li; Lijuan Jiang; Fangjian Zhou
Journal:  PLoS One       Date:  2016-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.